Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCentene Ambetter Formulary Coverage & PA Policy | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCentenePolicy N/A

    Ambetter Health Formulary (Prescription Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for all Centene policy alerts

    Know when Centene releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the Ambetter Health prescription drug formulary, tier structure, and coverage controls (prior authorization, step therapy, quantity/age limits) that govern pharmacy benefits for members covered by this plan.

    Policy Summary
    PayerCentene
    PolicyAmbetter Health Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionProviders must submit a Prior Authorization form when PA is indicated; urgent requests responded to within 24 hours and non-urgent within 72 hours.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Tier 0–4Formulary copay tiers defined
    7-dayOpioid new-start limits
    Tier 4Specialty tier
    24/72 hrsPA response timelines
    QL / ALQuantity/Age limits noted

    Formulary Coverage Criteria

    Formulary coverage rules

    Formulary coverage and tiering

    Formulary tiering and preferred agents: Preferred generics are first-line; preferred brand drugs are listed on Tier 2 when generics are unsuitable; specialty drugs are Tier 4 and may require specialty pharmacy fulfillment.

    See Formulary and Drug List Key

    Coverage controls: Products may be subject to utilization controls including prior authorization (PA), step therapy (ST), quantity limits (QL), age limits (AL), or be non‑formulary (NF) requiring an exception.

    Abbreviations and meanings defined in formulary key

    Opioid supply restrictions

    Opioid prescribing limits for new starts

    Opioid new-start quantity limits:
    Policy Summary
    PayerCentene
    PolicyAmbetter Health Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionProviders must submit a Prior Authorization form when PA is indicated; urgent requests responded to within 24 hours and non-urgent within 72 hours.
    SourceLink
    On This Page
    Formulary Coverage CriteriaFormulary Flags, Codes and Quantity/Age NotationsPrior Authorization, Step Therapy and Documentation RequirementsInitial Therapy and Site-of-Care ConsiderationsStep Therapy ApplicationsQuantity Limits, Age Limits and Fill RestrictionsAbbreviations and DefinitionsSpecialty Pharmacy and Fulfillment RequirementsBackground and ScopePolicy Revision History
    New therapy starts for opioid products are limited to a 7‑day supply. The formulary permits up to two 7‑day fills during any 28‑day period and up to a total of 28 non‑consecutive days of opioid supply within any 90‑day period; fills beyond these limits require prior authorization.
    two 7-day fills per 28 days; up to 28 non-consecutive days per 90 days

    Applies cumulatively to all opioid medications

    Starter kit/package limits

    Coverage for CYLTEZO/HUMIRA starter kits and similar specialty starter kits is limited by package and per-180-day fills

    Starter kit/package limits: Starter kits (e.g., CYLTEZO, HUMIRA pediatric starter kits) are subject to package limits and maximum fills over a 180‑day period (for example: package(s) per 180 day(s) retail/mail; max fill(s) per 180 day(s)) and often require prior authorization.package(s) per 180 day(s); max fill(s) per 180 day(s)

    Requests exceeding these package or max‑fill limits may be denied

    New start supply limits

    Analgesic and nonnarcotic entries include new-start supply limits

    Butalbital and select analgesics new start limit: Several butalbital-containing analgesics and certain aspirin products are designated 'New starts limited to 7 day supply'; quantity limits (e.g., QL(6 EA daily), QL(4 EA daily)) also apply per product.7 day supply for new starts

    Applies where 'New starts limited to 7 day supply' is present

    General coverage conditions

    Coverage includes product-specific tier assignment and utilization limits; many oral opioid products are covered with restrictions when ALL of the following apply:

    Common formulary conditions: Product is listed with a formulary tier; if labeled 'New starts limited to 7 day supply' the initial dispense is limited to 7 days; if a QL (quantity limit) is present the specified QL applies; if 'PA' is present prior authorization must be obtained prior to coverage.see individual QL/AL/PA entries

    Operational controls (QL/AL/PA/ST) govern coverage and dispensing

    General formulary coverage rules (partial)

    Coverage indicated with tier assignments and utilization controls

    Formulary entry: Drugs are assigned a formulary tier and may have associated utilization controls such as quantity limits (QL) and prior authorization (PA); these controls determine coverage and required documentation.

    This extract lists tier/QL/PA flags but does not include clinical diagnosis criteria within the lines cited

    Formulary coverage with PA/SP/QL flags

    Formulary coverage entries with utilization controls

    Formulary entries: Each listed drug has a tier assignment and may be subject to PA (prior authorization), SP (specialty pharmacy), and QL (quantity limits). Coverage is governed by those flags; providers must obtain PA or use SP when indicated.

    Specialty and PA flags commonly apply to oncology and specialty injectables in this segment

    Formulary tiering and utilization management

    Coverage is inferred by formulary tier and utilization management flags

    Tiering and utilization: Formulary tier (e.g., Tier 1B, Tier 3, Tier 4) combined with ILimits indicators (QL, PA, SP) defines coverage conditions and dispensing channel; specific clinical medical‑necessity criteria are not detailed in this excerpt.

    See tier definitions and ILimits entries

    Covered with conditions

    Formulary coverage with utilization management controls

    General formulary rules: Topical dermatologic agents are covered on specified tiers with common age limits (e.g., AL(At least 12 yrs old)) and quantity limits (QL); some topical products additionally require prior authorization or step therapy.see AL and QL per product

    Examples include clindamycin/benzoyl peroxide combinations (AL >=12; PA; QL specified)

    The formulary is a curated Prescription Drug List and is not a complete list of all covered products. Not all dosage forms or strengths may be covered, and the list is periodically reviewed and updated. Specific benefit plan designs may further exclude products or categories regardless of their appearance in this document; providers should verify member benefits and cost-sharing prior to dispensing.

    Within the extract there are no explicit clinical exclusions stated (e.g., blanket statements that particular diagnoses or patient groups are excluded). The entries shown instead apply utilization controls such as Prior Authorization (PA), Quantity Limits (QL), Age Limits (AL), and occasional Step Therapy (ST) requirements to govern coverage and dispensing.

    Some line items are placed on higher formulary tiers (for example, SUBSYS LIQD 800 MCG listed with Tier = 3 in the extract). Higher-tier placement typically indicates lower formulary preference and may result in increased member cost-sharing or additional utilization management before coverage.

    Certain antimalarial and related products are explicitly annotated as “Covered for malaria treatment only” and include restrictive fill limits (examples in the extract show Limit 1 fill every 180 days and package/mail QL values such as QL(24 EA per fill mail)). These entries should be considered treatment‑specific with limited repeat fills.

    The formulary flags some uses as requiring authorization when they are outside FDA‑approved indications. For example, certain scabicides/pediculicides (permethrin) list “Non‑FDA approved uses require Prior Authorization”. Requests for non‑FDA uses may be denied without an approved PA.

    Formulary Flags, Codes and Quantity/Age Notations

    Formulary flags and requirementsmixed
    QLQuantity Limit indicator used throughout drug listing
    ALAge Limit indicator used throughout drug listing
    PAPrior Authorization indicator used throughout drug listing
    STStep Therapy indicator used throughout drug listing
    Formulary quantity/age/prior auth notationsmixed
    QL(2 EA daily)Example quantity limit
    QL(280 ML per 56 day(s) retail)Quantity limit for tobramycin NEBU (example)
    AL(At least 6 yrs old)Age limit example
    QL(3.6 ML per 28 day(s) retail)Quantity limit example for injectables
    Package / max fill limitsmixed
    package(s) per 180 day(s) retailPackage-based limit over 180 days
    max fill(s) per 180 day(s)Maximum fills per 180-day period
    Formulary utilization and authorization codesmixed
    QL(6 EA daily)Quantity limit 6 each daily
    QL(4 EA daily)Quantity limit 4 each daily
    QL(100 ML daily)Quantity limit 100 mL daily
    QL(2 EA daily)Quantity limit 2 each daily
    QL(8 EA daily)Quantity limit 8 each daily
    QL(12 EA daily)Quantity limit 12 each daily
    AL(At least 45 yrs old Up to 79yrs old)Age limit applied to aspirin chew
    PAPrior authorization required
    Selected product strengths listedmixed
    150 MG/3MLamiodarone hcl SOLN 150 MG/3ML (as listed)
    300 MG/3MLenoxaparin sodium SOLN IJ 300 MG/3ML (as listed)
    5000 UNIT/ML, 10000 UNIT/ML, 20000 UNIT/MLheparin sodium (porcine) SOLN IJ concentrations (as listed)
    Formulary listed products (sample)mixed
    VALTOCO 20 MGVALTOCO 20 MG DOSE LQPK 10 MG/O.1ML
    VALTOCO 5 MGVALTOCO 5 MG DOSE LIQD
    dabigatran etexilate mesylate CAPSdabigatran etexilate mesylate CAPS
    Anticonvulsantsmixed
    lacosamide SOLN IV 200lacosamide SOLN IV 200
    APTIOM 200 MG, 400 MG, 600 MG, 800 MGlacosamide TABS (APTIOM)
    BANZEL TABS 200 MGrufinamide
    BRIVIACT SOLN PO 10 MG/MLBRIVIACT solution
    Miscellaneous CNS and diabetes drugsmixed
    topiramate TABS 200 MGtopiramate TABS 200 MG
    TRINTELLIXTRINTELLIX
    JANUMET XR TB24 1000 MG-100 MGJANUMET XR
    Opioid antagonists / related productsmixedCovered
    naloxone hcl LIQDnaloxone liquid formulations listed with ILimits and tier
    naloxone hcl SOLN 0.4 MG/ML, 4 MG/10MLnaloxone solution formulations
    naltrexone hclnaltrexone listed (Tier = 1B)
    Insulins and diabetes productsmixedCovered
    APIDRA SOLOSTAR SOPNAPIDRA SOLOSTAR insulin pen (PA indicated)
    HUMULIN R U-500 (CONCENTRATED) SOLN SCConcentrated insulin with QL limits
    INSULIN ASPART FLEXPEN SOPNInsulin aspart pen
    AntifungalsmixedCovered
    fluconazole TABSfluconazole tablets
    posaconazole SUSPposaconazole suspension (Tier = 3)
    voriconazole TABSvoriconazole tablets
    Antiemetics / 5-HT3 antagonistsmixedCovered
    granisetron hcl SOLN IV 1 MG/MLgranisetron IV solution
    ondansetron hcl SOLN IJ 4 MG/2 MLondansetron injectable solution
    ondansetron hcl TABS 24 MGondansetron tablets 24 mg
    Quantity limit expressions from formularymixed
    QL(1 EA daily)Quantity limit example shown in multiple entries
    QL(2 EA daily)Quantity limit example shown in multiple entries
    QL(4 EA daily)Quantity limit example shown in multiple entries
    No CPT/HCPCS/ICD-10/NDC codes presentmixed
    No codes listed
    No procedure/diagnosis codes present in this excerptmixed
    No codes listed
    Listed product names (not CPT/HCPCS)mixed
    NOVAREL IM 10000 UNITproduct line as printed
    EGRIFTA SVproduct line as printed
    GENOTROPIN MINIQUICK PRSYproduct line as printed
    NORDITROPIN FLEXPRO SOPN 30 MGI3MLproduct line as printed
    inv-41: Opioid new-start supply limits
    Opioid new-start supply policyUp to two 7-day fills during any 28-day period; up to 28 non-consecutive days in any 90-day period
    Applies toAll opioid medications filled — limit applies cumulatively across opioids
    Exceeding the limitFills exceeding these limits require submission of a Prior Authorization request
    inv-42: New starts supply limit
    New-start opioid supply limitInitial prescriptions for specified opioids are limited to a 7-day supply for new therapy starts
    Context examplesLanguage 'New starts limited to 7 day supply' appears on multiple analgesic and opioid line items
    DocumentationPrescribers should document indication and intended short supply when requesting fills exceeding the new-start limit
    inv-46: Naloxone retail fills
    Naloxone retail quantity limitQL(2 EA per retail)
    Max fills per period2 max fill(s) per 30 day(s) retail
    ImplicationExceeding QL or max fills may trigger denial or require PA
    inv-47: Insulin QL examples
    HUMULIN R U-500 exampleQL(1.34 ML daily)
    Other insulin QL examplesQL(4 EA daily); QL(2 EA daily) — quantity limits vary by insulin product presentation
    Follow line-item QLApply the specific QL shown for each insulin product as listed on the formulary

    Prior Authorization, Step Therapy and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization (PA) is required for many drugs listed on the formulary. Providers must submit a completed Prior Authorization form with all supporting clinical documentation. Urgent requests will be responded to within 24 hours of receipt of all necessary information; non‑urgent requests will be responded to within 72 hours unless state law requires a faster response. If a request is disapproved or incomplete, the notice will explain the specific reasons for denial or identify missing information needed to complete the request.

    • PA applies to non‑formulary drugs and to formulary products specifically indicated with 'PA' in the formulary ILimits/Drug Requirements field.
    • Some products also require specialty pharmacy (SP) handling or are flagged as SP; PA must be obtained when SP is indicated.
    • Formulary abbreviation reminders: PA = Prior Authorization; QL = Quantity Limit; ST = Step Therapy; NF = Non‑formulary; SP = Specialty Drug; AL = Age Limit; SF = Split Fill.
    Denial Risk

    Quantity Limits, Packaging and Denial Risk

    Prior authorization and quantity/packaging limits interact: requests that exceed posted quantity limits (QL), package limits (for example, packages per 180 days), or max fills per period will require documentation and may be denied without prior approval. For biologics, specialty agents, and starter kits the formulary often lists package or max‑fill restrictions that trigger PA and additional documentation requirements.

    • Requests exceeding QL or package(s) per X days require justification and supporting clinical documentation; exceedances may be denied if not justified.
    • Starter kits and multi‑package products (e.g., certain biologic starter packs) include package limits per 180 days — submit documentation when requesting exceptions.
    • New starts on select opioids and other controlled substances are limited (for example, new starts limited to 7 days supply); requests for larger or continuation supplies require PA and quantity justification.
    Documentation Required

    Documentation Requirements for PA/SP

    When PA or SP is indicated on the formulary line, providers must include specialty documentation (when applicable) and follow the formulary entry notes. Documentation should include diagnosis, prior therapies (including dates and outcomes), age if an age limit (AL) applies, dosing, quantity requested and rationale for requests exceeding QL or 'new start' limits.

    • Include age and quantity justification when AL or QL are present on the formulary line.
    • For PA requests on specialty biologics or oncology agents (lines flagged SP; PA) include relevant specialty documentation: indication, prior treatments, weight when dose is weight‑based, and prior authorization history.
    • For non‑FDA uses flagged on the formulary (notes indicating 'approved uses require Prior Authorization' or 'Non‑FDA approved uses require Prior Authorization') attach supporting clinical rationale and literature as appropriate.
    Step Therapy

    Step Therapy Requirements

    Step therapy (ST) requirements are present for select agents. If a formulary entry lists ST or a specific required trial (for example, 'Must try ibuprofen; ST'), the prerequisite therapy must be documented before PA will be approved unless an exemption criterion is met.

    • Step therapy flags appear on anticonvulsants, topical agents, and some biologic entries — document trials of required agents with dates and outcomes.
    • Failure to meet step therapy requirements may result in denial; appeals should include rationale for bypassing the step (e.g., intolerance, contraindication).
    • Some entries list ST but no algorithm in the excerpt — follow the payer's step therapy guidance or prior authorization instructions when submitting requests.
    Billing Rule

    Follow Formulary Limits and Channel Requirements

    Follow the formulary entry notes (QL / PA / SP / ST / AL) shown on each line when submitting claims or PA requests. Items marked PA or SP; PA require prior authorization and/or specialty channel enrollment prior to dispensing and may be denied if those requirements are not met.

    • Line‑level indicators: PA = prior authorization required; QL = quantity limit applies; SP = specialty pharmacy requirement; ST = step therapy; AL = age limit.
    • Claims submitted without required PA or through non‑specialty channels when SP is indicated may be denied or delayed.
    • When both SP and PA are listed, ensure enrollment with the specialty pharmacy and obtain PA documentation prior to dispensing.

    Initial Therapy and Site-of-Care Considerations

    Initial therapy restrictions

    Initial prescribing restrictions seen in the extract

    Initial supply limit: For many opioid products the 'New starts limited to 7 day supply' restriction applies to initial therapy; prescribers requesting an initial supply exceeding this limit should submit documentation and prior authorization per formulary instructions.7 day

    Applies where 'New starts limited to 7 day supply' is present; see opioid policy for cumulative limits

    Initial coverage considerations for pulmonary hypertension agents

    Initial coverage considerations for pulmonary hypertension agents

    PA/SP requirement: Pulmonary hypertension agents (including prostacyclins and pulmonary formulations) are commonly designated with PA and/or SP, indicating prior authorization and specialty pharmacy dispensing are required before coverage and fulfillment.

    No specific medical‑necessity diagnostic criteria provided in this excerpt; follow PA/SP processes when indicated

    Step Therapy Applications

    Step therapy contextExamples / NotesCoverage label
    Step therapy (ST) may require a member to try specified lower‑tier or preferred agents before coverage of alternative products is allowed.Applied to certain stimulant/anorexiant and ADHD agents (examples include lisdexamfetamine dimesylate listed with 'QL(1 EA daily); ST' and other amphetamine/dextroamphetamine entries showing ST/QL), indicating a prerequisite trial of preferred agents may be required.
    Formulary entries show ST flags alongside QL and PA; providers should document prior trials when ST is indicated.Examples: lisdexamfetamine dimesylate CAPS — 'QL(1 EA daily); ST'; amphetamine/amphetamine combinations show QL and PA annotations that may imply step requirements.
    [{"text":"See formulary ILimits: 'ST' indicates step therapy applies and may block coverage until prerequisite therapy is tried.","status":"neutral"},{"text":"Member-specific coverage depends on completing required steps or obtaining an exception/PA as applicable.","status":""},{"text":"","status":""}
    ProductStep requirementCoverage label
    ACTEMRA SOLN 80 MG/1ML'Must try ibuprofen; ST' — documentation of prior trial of ibuprofen is required before ACTEMRA SOLN 80 MG/1ML is covered.
    ACTEMRA SOLN (other strengths)Line entries for ACTEMRA solutions also list QL(20 mL per 28 days) or QL(40 mL per 28 days) and specialty pharmacy (SP) for some presentations; the 80 mg/1 mL strength explicitly requires trying ibuprofen first.
    Drug / classST indicator in listingCoverage label
    APTIOM (lacosamide) 200–800 mgILimits = QL(2 EA daily); ST — step therapy flag present for some APTIOM entries.
    Eslicarbazepine acetate (various)ILimits = QL(2 EA daily); ST — indicates step therapy may be required for certain strengths/forms.
    Other anticonvulsants (lacosamide IV, rufinamide/BANZEL)Multiple anticonvulsant entries include QL and some include ST or PA flags, suggesting step edits or prior authorization may apply depending on product.
    ImplicationEvidence from formularyCoverage label
    Tier-based placement implies preferred agents may be required prior to coverage of higher-tier products.Several branded or combination products are listed at higher tiers (Tier = 2 or 3) and some ILimits include 'ST', indicating tier-preferred agents could be step requirements though explicit fail-first sequences are not provided.
    No explicit step-failure rules in extractThe document states 'No explicit step therapy sequences are provided in this excerpt' — tiering suggests implication but not formalized algorithms.
    Item / categorySP / PA notation shownCoverage label
    Select high-tier oncology and anti-infective agents (examples: fludarabine, gemcitabine entries)Many antineoplastic entries include 'SP; PA' or 'PA' indicating specialty pharmacy routing and prior authorization are required.
    ACTEMRA SOLN presentationsSome ACTEMRA listings note SP and QL values for specific strengths, consistent with specialty handling for certain presentations.
    Topical productST noted / ILimitsCoverage label
    Clindamycin phosphate‑tretinoin combinationsILimits = AL(At least 12 yrs old); ST — step therapy specified for selected topical combination products.
    Clindamycin phosphate‑benzoyl peroxide (various)ILimits include AL(At least 12 yrs old); PA; QL(15 GM per 30 days) — some formulations have ST noted in adjacent topical entries.
    Tretinoin formulationsMultiple tretinoin entries list QL values and some list ST where step therapy applies for topical retinoid combinations.
    Topical formulationST / ILimitsCoverage label
    Clobetasol propionate FOAMILimits = QL(3 GM daily); ST — clobetasol foam is explicitly listed with a step therapy requirement.
    Clobetasol gel/ointment/solutionVarious clobetasol formulations include QL and ST or PA flags (e.g., QL(2 GM daily); ST or QL(1 GM daily); PA) depending on formulation.
    Diuretic / related productSP / ST / ILimits notedCoverage label
    Bumetanide SOLN 0.25ILimits = QL(0.143 EA daily); PA — listed with QL and PA; some presentations reference SP indicating specialty routing for certain forms.
    Bumetanide TABSILimits = QL(5 EA daily); some bumetanide tablet entries include SP; PA indicating step or specialty requirements per line-item.
    Furosemide, torsemide, spironolactone, triamterene & HCTZSeveral diuretics are shown with 'SP; PA' or ILimits that reference ST or specialty handling (e.g., furosemide SOLN PO listed with SP; PA; triamterene CAPS with QL).

    Quantity Limits, Age Limits and Fill Restrictions

    inv-166: Stimulants and related QLs
    Common stimulant QLsExamples include QL(1 EA daily), QL(2 EA daily), QL(4 EA daily)
    Large-volume nebulized exampleQL(280 ML per 56 day(s) retail; 280 ML per 56 days mail)
    Daily-limit patternMany stimulant/related agents use EA-per-day QL expressions (apply per line item)
    Variation by strength/formSpecific QL varies by product strength and dosage form — use the line-item QL
    inv-167: Opioids (new starts)
    Opioid new-start rules (summary)Allow up to two 7-day fills during any 28-day period; up to 28 nonconsecutive days in any 90-day period
    Applies toAll opioid medications identified with 'New starts limited to 7 day supply'
    Authorization for excessPrior Authorization required for fills exceeding these limits
    inv-170: CYLTEZO / HUMIRA starter kits
    Starter kit/package limitPackage(s) per 180 day(s) retail/mail (starter kits limited to specified packages per 180 days)
    Examples of QL in kitsSpecific presentations list QL values (e.g., QL(0.215 EA daily) for certain CYLTEZO presentations)
    AuthorizationThese starter kits often require Prior Authorization (PA) per line-item
    inv-171: ACTEMRA SOLN quantity limits
    ACTEMRA SOLN quantity limitsQL(40 ML per 28 day(s) retail/mail) and QL(20 ML per 28 day(s)) depending on strength
    80 mg/1 mL strength noteACTEMRA SOLN 80 MG/1ML entries include QL(20 ML per 28 day(s)) and may note 'Must try ibuprofen; ST'
    Specialty routingSome ACTEMRA presentations are noted SP and may require specialty pharmacy handling and PA
    inv-172: Butalbital/aspirin new-start limits and QLs
    New-start limit for butalbital/aspirin entriesNew starts limited to 7 day supply (applies to several butalbital and aspirin line items)
    Quantity limit examplesQL(6 EA daily); QL(4 EA daily) shown for various formulations
    Prior Authorization flagSome line items also include PA — follow line-item requirements
    inv-173: Multiple product QL examples
    Multiple product QL examplesVaries by product; examples include QL(6 EA daily); QL(4 EA daily); QL(100 ML daily); QL(8 EA daily); QL(12 EA daily)
    Apply per line itemEach product listing specifies the applicable QL — use the exact line-item value
    Dose/strength dependentQLs differ by strength, form, and therapeutic class
    inv-183: Naloxone QL and max fills
    Naloxone QL per retailQL(2 EA per retail)
    Max fills per 30 days (retail)2 max fill(s) per 30 day(s) retail
    Denial riskExceeding these limits may trigger denial or require PA
    inv-184: HUMULIN R U-500 QL example
    HUMULIN R U-500 QL exampleQL(1.34 ML daily)
    Product-class noteConcentrated insulins list product-specific ML/day QLs in formulary entries
    Follow line-item ILimitsUse the exact ILimits shown for the specific insulin presentation
    inv-192: Malaria product limits
    Malaria product fill limitLimit 1 fill every 180 days
    Mail fill QL exampleQL(24 EA per fill mail)
    Covered useSome malaria products are listed 'Covered for malaria treatment only' with these fill limits
    inv-201: STELARA specialty injectable limits
    STELARA mail QLQL(60 GM per fill mail)
    Retail max fill1 max fill(s) per 30 day(s) retail
    Specialty/PA noteSTELARA entries include ILimits and may require PA/SP handling
    inv-204: DUPIXENT fill/QL example
    DUPIXENT QL exampleQL(0.082 ML daily)
    Fill frequency limitsMax fill(s) per 30 day(s) retail; mail fill limits specified per presentation
    PA requiredDUPIXENT line items include PA in ILimits
    inv-205: TRUE METRIX test strips QL
    TRUE METRIX test strips QLQL(3.34 EA daily)
    OTC/Rx noteTRUE METRIX listed with RX/OTC designation in ILimits
    Apply per-day QLLimit expressed as EA per day — follow line-item limit
    inv-206: triamterene & hydrochlorothiazide QL example
    Triamterene & HCTZ QL exampleQL(0.143 EA daily)
    Formulation noteQL differs between capsule and tablet listings — check line-item
    Apply daily QLLimit expressed as EA per day
    inv-209: hydrochlorothiazide QL example
    Hydrochlorothiazide QL exampleQL(2 EA daily)
    Strength rangeApplies to HCTZ 12.5–50 mg line items as shown
    Follow specific ILimitsUse the exact QL on the formulary line-item for dispensing limits
    inv-210: metoclopramide QL example
    Metoclopramide solution QLQL(60 ML daily)
    Formulation-specificApplies to metoclopramide HCl solution oral presentations as listed
    Provider documentationPrescribers should document indication when requesting quantities exceeding QL
    inv-211: mesalamine QL example
    Mesalamine TBEC QLQL(6 EA daily)
    Product formSpecifically shown for mesalamine TBEC 800 mg line-item
    Apply per-day limitLimit expressed as EA per day — follow line-item QL

    Abbreviations and Definitions

    inv-116: Formulary / Prescription Drug List
    DefinitionFormulary / Prescription Drug List: A list of FDA‑approved brand and generic drugs covered under the prescription benefit; not exhaustive and subject to periodic updates.
    PurposeIdentifies covered drugs, tier placement, and associated utilization controls (QL, PA, ST, AL)
    Coverage noteNot all dosage forms or strengths may be covered; check the benefit plan for limitations
    inv-117: Abbreviations (AL, QL, PA, ST, NF, RX/OTC, SP, SF)
    ALAge Limit — indicates coverage only for specified ages (e.g., AL(At least 12 yrs old)).
    QLQuantity Limit — maximum allowed quantity per time period as presented in formulary entries (e.g., QL(2 EA daily)).
    PAPrior Authorization — requires provider to obtain approval before coverage when indicated (noted as 'PA').
    STStep Therapy — requires trial of specified lower-step drug(s) before coverage of another agent (noted as 'ST').
    NFNon‑formulary — product not covered unless an exception is granted
    RX/OTCPrescription and Over‑the‑Counter designation — indicates both forms may exist
    SPSpecialty Drug — may require specialty pharmacy routing and handling
    inv-118: QL
    QL (Quantity Limit) definitionQuantity Limit as presented in formulary entries (e.g., QL(2 EA daily); QL(280 ML per 56 day(s))).
    Unit formatsQL expressions use units such as EA (each), ML (milliliter), GM (gram), or per-fill and per-period formats
    PurposeSpecifies maximum quantity allowed per day, per fill, or per period — exceeding QL may require PA or be denied
    inv-119: AL
    AL (Age Limit) definitionAge Limit as presented in formulary entries (e.g., AL(At least 6 yrs old); AL(At least 12 yrs old)).
    ApplicationSpecifies minimum and/or maximum ages for coverage of a product or formulation
    DocumentationAge may need to be documented when requesting PA or override of an AL
    inv-121: New starts limited to 7 day supply
    Definition - New starts limited to 7 day supplyA formulary restriction that limits the initial prescription of certain opioid products to a maximum 7‑day supply for new therapy starts
    ScopeApplied to many oral opioid and select analgesic line items as noted on the formulary
    Exceeding the limitFills beyond the new‑start 7‑day supply require submission of a Prior Authorization request
    inv-128: Tier
    TierFormulary tier designation indicating coverage level or member cost‑sharing category (e.g., Tier 0–4); Tier 4 is specialty with highest copayment
    UseTier guides member cost-sharing and may influence step therapy or preferred agents
    Specialty tier noteSpecialty (Tier 4) products may require fulfillment at specialty pharmacies
    inv-133: PA
    PA (Prior Authorization)Prior Authorization indicates the provider must obtain approval before coverage when 'PA' appears in the formulary ILimits
    When requiredMany biologics, specialty agents, and selected formulations list 'PA' — follow the line-item note
    Submission timelinesUrgent PA requests are responded to within 24 hours; non‑urgent within 72 hours unless state law requires faster response
    inv-137: Specialty Pharmacy
    Specialty Pharmacy (SP)SP indicates specialty pharmacy routing requirement; specialty drugs may require fulfillment at participating specialty/hemophilia network pharmacies
    When appliedUsed for many injectable, biologic, and complex therapies listed on the formulary
    PA often accompanies SPSP entries commonly appear with PA — providers should confirm specialty channel and authorization requirements
    inv-142: AL example
    AL exampleAL(At least 12 yrs old) — example age‑limit notation used in topical dermatologic entries
    UsageAL expressions specify minimum (and sometimes maximum) ages for coverage
    Check line itemApply the specific AL shown on the formulary line for the product and formulation

    Specialty Pharmacy and Fulfillment Requirements

    Note
    Note
    Note

    Background and Scope

    The formulary distinguishes preferred generics as first‑line treatment options and identifies preferred brand drugs (e.g., placed on Tier 2) when generics are unsuitable. Specialty agents are assigned top tier placement and often require specialty pharmacy handling; these products may also be subject to Prior Authorization (PA), Step Therapy (ST), or Quantity/Age Limits (QL/AL) as noted on their formulary line entries.

    Policy Revision History